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Abstract : Germline mutations of BRCA1 / 2 genes cause hereditary breast and /
or ovarian cancer.  However, whether guidelines like those of the National 
Comprehensive Cancer Network （NCCN） can suitably predict the likelihood of 
BRCA1 / 2 mutations in the Japanese population is unclear.  Methods BRCA1 / 2 
gene mutation frequencies were investigated in relation to parameters such as 
age, family history （FH）, and breast cancer subtype using data collected from 
922 Japanese breast cancer patients who underwent surgery between September 
2010 and June 2013.  BRCA1 / 2 mutations were present in 15 of 57 （26.3％） 
tested patients. The frequency of the mutations was not signicantly related to age.  
Among the 180 patients who reported an FH of breast cancer, 11 of the 37 who 
were tested （29.7％） were positive for BRCA1 / 2 mutations.  Of those with an 
FH of ovarian cancer （n＝ 34）, seven of 12 patients tested （58.3％） were carriers 
of BRCA1 / 2 （P＝ 0.013）.  Six of these seven carriers were triple-negative breast 
cancer （TNBC） patients.  In all, there were 97 TNBC patients, and the presence 
of the BRCA1 / 2 mutation in this subgroup was signicantly greater than in non-
TNBC patients, with 12 of 17 TNBC patients （70.5％） testing positive （P＝ 0.03）.  
There were 59 TNBC patients ＜60 years of age, and of the 16 （27.1％） who 
underwent BRCA1 / 2 genetic testing, 11 （68.8％） were found to have mutations in 
BRCA1 / 2.  Among the TNBC patients, 29 also reported an FH of breast or ovar-
ian cancer ; of these, nine of the 13 tested （69.2％） were positive for a BRCA1 / 2 
mutation.  The data demonstrate that BRCA1 / 2 mutations are observed more 
frequently in TNBC patients, especially those ＜60 years of age or in combination 
with an FH of breast and / or ovarian cancer, suggesting that some of the NCCN 
guidelines can adequately predict BRCA1 / 2 carriers in the Japanese population.
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Introduction
　BRCA1（MIM 113705） and BRCA2（MIM 600185） are autosomal dominant tumor suppressor 
genes that mediate the DNA damage response to double-stranded DNA breaks by homologous 
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recombination.  Germline mutations of these two genes are associated with the early onset and /
or familial forms of breast cancer.  According to previous reports, BRCA1 / 2-related breast 
cancer accounts for approximately 5％～ 10％ of all breast cancers diagnosed 1）.  It is estimated 
that, by 70 years of age, the average cumulative risk of breast cancer in carriers of BRCA1 
and BRCA2 mutations is in the range 60％～ 70％ and 45％～ 55％, respectively 2-5）.  Notably, 
triple negative breast cancer （TNBC） is more common in individuals with the BRCA1 mutation 
than in those without this mutation.  TNBC is defined as an absence of staining for estrogen 
receptor, progesterone receptor, and Her2 / neu.  TNBC accounts for approximately 15％ of all 
breast cancers, and 70％ of individuals with the BRCA1 mutation have TNBC 2, 6）.  In ovarian 
cancer, the risk of TNBC has been estimated to be 40％ and 20％ for carriers of BRCA1 and 
BRCA2 mutations, respectively 3, 4）.  Furthermore, carriers of BRCA1 and BRCA2 mutations are 
at an increased risk of developing fallopian tube, colon, prostate and pancreatic cancers, as well 
as melanoma 2, 4, 5）.  It is well known that Ashkenazi Jews have a high frequency of BRCA1 / 2 
mutations 5）.  Recently, several studies have reported that Asian populations have a similarly high 
frequency of BRCA1 / 2 mutations 7–9）.  In Japan, the actual frequency of BRCA1 / 2 mutations 
in the general population is not clear.  Moreover, there is a tendency for earlier onset of disease 
and a higher frequency of hormone receptor-positive tumors in Japanese breast cancer patients 
compared with Caucasian populations 10–12）.  Furthermore, the National Comprehensive Cancer 
Network （NCCN） has published guidelines about risk reduction after genetic assessment of 
breast and ovarian cancer 13）.  However, because the characteristics of breast cancer in Japanese 
BRCA1 / 2 carriers may differ from those of Caucasian women, it is not clear whether these 
guidelines are suitable for the Japanese population.  Therefore, the purpose of the present study 
was to determine the occurrence of BRCA1 / 2 mutations in Japanese breast cancer patients, and 
its association with factors such as age, family history （FH）, and cancer subtype, and to consider 
the eligibility criteria for BRCA1 / 2 genetic testing in comparison with the NCCN guidelines. 
Herein we report the findings of an investigation regarding the outcomes of BRCA1 / 2 genetic 
testing and mutations in Japanese breast cancer patients receiving treatment at Showa University 
Hospital.
Patients and methods
　Nine hundred and twenty-two Japanese breast cancer patients who underwent surgery at 
Showa University Hospital between September 2010 and June 2013 were included in the study. 
Detailed patient information was collected from medical records and included personal history, 
FH, breast cancer clinicopathological data, and the BRCA1 and BRCA2 mutation status.  Genet-
ic counseling was recommended to patients according to NCCN guidelines.  Specically, genetic 
counseling was recommended to patients with : （1） an FH of breast and / or ovarian cancers ; 
（2） early onset, especially ＜40 years of age ; （3） TNBC at ＜60 years of age ; and （4） bilateral 
breast cancer.  Patients were determined to have a positive FH when a rst-, second-, or third-
degree relative had had breast or ovarian cancer.  Doctors and certified genetic counselors 
administered a structured questionnaire to women who gave informed consent to receive genetic 
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counseling as part of this study.
　Blood samples obtained from patients were analyzed for the presence of BRCA1 / 2 mutations 
at Falco Biosystems （Kyoto, Japan） using a direct sequencing method.  If mutations were not 
detected using this method, samples were subjected to multiplex ligation-dependent probe ampli-
cation （MLPA） to check for BRCA1 / 2 genetic rearrangements.
　Statistical analyses of BRCA1 / 2 genetic mutations were performed using SPSS version 19 
（SPSS, IBM, Chicago, IL, USA）.  Pearson’s χ2 test and Fisher’s exact test were used to evalu-
ate associations between patient characteristics and genetic mutations.  All P-values are two-sided 
and signicance was set at P＜ 0.05.
Results
Clinicopathological characteristics of the Japanese breast cancer patient cohort
　The characteristics of all patients who underwent surgery for breast cancer at Showa Univer-
sity Hospital are given in Table 1.  Briey, 922 patients with a median age of 52.2 years （range 
Table 1.  Characteristics of the patient cohort
No. patients 922
Sex
　Female 919
　Male 3
Age（years）
　Range 22–97
　Median 52.2
Tumor size
　DCIS 159
　≤ 2 cm 455
　＞2 cm，≤ 5 cm–＞2 cm，≤ 5 cm 176
　＞5 cm 33
　Unknown 99
Lymph nodes
　Negative 660
　Positive 205
　Unknown 57
Estrogen receptor
　Negative 159
　Positive 711
　Unknown 52
Progesterone receptor
　Negative 295
　Positive 574
　Unknown 53
Her2
　Negative 629
　Positive 146
　2＋ 93
　Unknown 8
Bilateral breast cancer
Family history of :
　Breast cancer 180
　Ovarian cancer 34
Data show the number of patients in each group.
DCIS, ductal carcinoma in situ ; Her2, epidermal growth factor receptor 2.
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22～ 97 years） were recruited to the study.  Four hundred and two patients （43.6％） were ＜ 50 
years of age.
BRCA1 / 2 mutation frequency according to age and FH in Japanese breast cancer patients
　The number of patients who underwent genetic testing for BRCA1 / 2 mutations and the 
results of these tests are given in Table 2.  One hundred and sixteen（12.6％） patients received 
genetic counseling and, of these, 57（6.2％） agreed to a BRCA1 / 2 genetic test.  Testing revealed 
that 15 of those patients（26.3％） harbored BRCA1 / 2 germline mutations.  BRCA1 mutations 
were detected in 11 patients, whereas BRCA2 mutations were detected in four.  Of the 11 
patients with a BRCA1 mutation, two rearrangement mutations were detected.  There was a 
tendency for a greater number of younger patients to receive genetic counseling and to agree 
to BRCA1 / 2 genetic testing.  Specically, counseling rates were 25.4％ and 33.3％ for patients 
＜45 and ＜40 years of age, respectively.  According to the NCCN guidelines, patient age ＜50 
years is one of the criteria for genetic counseling ; thus, according to the NCCN guidelines, 554 
patients in our cohort（60.1％） were eligible for genetic counseling.  When the age criterion was 
reduced from ＜50 to ＜40 years old, 313 patients（34％） were eligible for counseling.  Of these, 
87（27.8％） received genetic counseling and 45（14.3％） underwent genetic testing, of whom 12
（26.6％） were positive for the BRCA1 / 2 genetic mutation.  There was no signicant difference 
in BRCA1 / 2 mutation frequencies according to age.  Indeed, after genetic testing of patients ＜
50 years of age, 13 of 40（23.5％） were found to be positive for BRCA1 / 2 mutations, which 
does not differ signicantly from the rate in patients ＞50 years of age（2 / 17［11.8％］; P＝
0.18）.  In the case of patients ＜40 years of age, seven of the 22（31.8％） who underwent test-
ing were positive for BRCA1 / 2 mutations.  This rate was not signicantly different from the 
rate in patients ＞40 years of age（8 / 35 ［22.9％］; P＝ 0.66）.
　Similarly, an FH of breast cancer in our patient cohort did not signicantly increase the risk 
of BRCA1 / 2 mutations compared with no FH of breast and / or ovarian cancer（11 / 37 vs 
3 / 16, respectively ; P＝0.51）.  Of the 180 breast cancer patients with an FH of breast cancer, 71 
（39.4％） received genetic counseling, 37（20.6％） underwent BRCA1 / 2 genetic testing, and 11 
of the 37（29.7％） were found to be carriers.  Thirty-four breast cancer patients also reported an 
FH of ovarian cancer.  In this patient subset, 14（41.2％） received genetic counseling, 12（35.3％） 
underwent BRCA1 / 2 genetic testing, and seven（58.3％） were found to be BRCA1 / 2 positive, 
suggesting that there is a signicantly higher rate of mutations in patients with an FH of ovarian 
cancer compared with all patients reporting an FH of cancer in general（7 / 12 vs 12 / 41, respec-
tively ; P＝ 0.013）.  The number of patients with an FH of both breast and ovarian cancer was 
small（12 / 922）, but the rate of BRCA1 / 2 mutations in this group was very high.  Indeed, of 
the eight patients with an FH of both breast and ovarian cancer who underwent genetic testing, 
six（75％） were found to be positive for BRCA1 / 2 mutations.
BRCA1 / 2 mutation frequency according to age and FH in Japanese TNBC patients
　From a biomarker point of view, TNBC accounted for 97 cases（10.5％）, with a mean patient 
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age of 54.9 years.  The average age of TNBC patients who received genetic counseling was 43 
years, whereas that of TNBC patients who underwent genetic testing was 39.2 years.  Of the 17
（17.5％） TNBC patients who underwent BRCA1 / 2 genetic testing, mutations were detected in 12
（70.6％）, which was signicantly（P＝ 0.03） higher than the detection rate in non-TNBC patients. 
Almost all patients who received genetic testing were ＜60 years of age （16 / 17 ; 94.1％）.  There 
were 59 TNBC patients ＜ 60 years of age, and they exhibited high BRCA1 / 2 mutagenesis rates. 
Among the 16 of 59 patients（27.1％） who underwent BRCA1 / 2 genetic testing, 11（68.8％） 
were found to have mutations.  Thus, even though not all patients underwent genetic testing, the 
mutation rate is likely to be at least 18.6％（11 / 59） in TNBC patients ＜ 60 years of age.  For-
ty-three TNBC patients were ＜ 50 years old, and 15（34.9％） of this patient subset underwent 
BRCA1 / 2 genetic testing, with 10（66.7％） being found to be positive for BRCA1/2 genetic 
mutations.  The BRCA1 / 2 mutation rate was also examined in TNBC patients with an FH of 
breast or ovarian cancer（n＝29）.  This subset of patients was found to have an even higher 
mutagenesis rate than patients without an FH of breast or ovarian cancer.  Indeed, of the 29 
Table 2.  BRCA1 / 2 status in Japanese breast cancer patients according to different criteria
n
Genetic 
counseling
Genetic 
testing
BRCA1 / 2 
mutation
BRCA1 
mutation
BRCA2 
mutation
P-value
Age（years）
　All 922 116 57 15 11 4
　≤ 50 402 86 40 13 10 3
　≤ 45 264 67 35 13 10 3
　≤ 40 129 43 22 7 6 1
　≤ 35 49 25 13 1 0 1
Family history of :
　Breast and ovarian cancer 720 41 16 3 3 0 0.51
　Breast or ovarian cancer 202 75 41 12 8 4
　　Breast cancer 180 71 37 11 8 3
　　Ovarian cancer 34 14 12 7 5 2
　　Breast and ovarian cancer 12 9 8 6 5 1
Biomarker
　Non-TN 825 91 40 3 1 2 0.03
　TN 97 25 17 12 10 2　
　　TN（≤ 60 years） 59 21 16 11 10 1
　　TN（≤ 50 years） 43 20 15 10 9 1
　TN with a family history of : 
　　Breast or ovarian cancer 29 18 13 9 7 2
　　Breast cancer 20 12 7 3 3 0
　　Ovarian cancer 4 1 1 1 0 1
　　Breast and ovarian cancer 5 5 5 5 4 1
Data show the number of patients in each group.
TN, triple negative.
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patients with a positive FH, 13（44.8％） underwent BRCA1 / 2 genetic testing and nine（69.2％） 
were found to be positive.  In particular, TNBC patients with an FH of ovarian cancer had a 
very high mutagenesis rate.  Six of the nine patients who had an FH of ovarian cancer（66.6％） 
underwent genetic testing and all six were found to be positive for BRCA1 / 2 mutations.
Discussion
　In the present study, BRCA1 / 2 mutations were most frequently observed in TNBC patients, 
especially those ＜ 60 years of age and with an FH of breast or ovarian cancer.
　In general, genetic testing is recommended when the mutation rate is estimated to be ＞ 10％. 
Some reports have estimated that the rate of BRCA1 / 2 mutations across all TNBC is 10％～
20％ 14–16）.  According to NCCN guidelines, this is the borderline predicted risk rate recommended 
for TNBC patients to undergo BRCA1 / 2 genetic testing.
　Two of the parameters used to determine eligibility for BRCA1 / 2 genetic testing are FH and 
age. The NCCN guidelines for familial breast cancer recommend that breast cancer patients in 
the following categories undergo the BRCA1 / 2 genetic test : （1） patients with early age onset 
breast cancer, especially ＜ 45 years of age ; （2） breast cancer patients ＜ 50 years of age who 
have more than one close blood relative （i.e. rst-, second-, and third-degree relatives ; the same 
applies hereafter） with breast cancer ; （3） breast cancer patients who have more than one close 
blood relative with epithelial ovarian cancer, or more than two close relatives with breast cancer 
and / or pancreatic cancer ; （4） multiple primary breast cancers ; （5） a combination of breast 
cancer with a BRCA1 / 2-related cancer ; and （6） male breast cancer.  In 2011, the NCCN pub-
lished updates to include patients with TNBC diagnosed at ＜ 60 years of age and breast cancer 
patients with more than two close blood relatives with pancreatic cancer at any age13）.  The 
intrinsic subtype of breast cancer is also being considered in addition to FH as a prerequisite to 
determine the need for BRCA1 / 2 genetic testing.
　The NCCN guidelines recommend genetic counseling for patients ＜50 years of age.  However, 
in the present study the median age of all breast cancer patients was 52.2 years old ; thus, 554
（60.1％） patients were eligible for counseling.  This number is relatively large and impractical. 
We then modied the age criterion to ＜ 40 years of age, which resulted in 313（34％） patients 
who were eligible for counseling.  Using this modied age criterion, we were able to identify 
80％ of all patients with BRCA1 / 2 mutations in the present study.  Therefore, this modication 
seems to be appropriate for Japanese women.  Notably, the NCCN guidelines also recommend 
that a separate FH for both paternal and maternal lines is obtained.  However, there was not 
sufcient information in our clinical database to meet this criterion; therefore, the actual rate of 
a positive FH may be larger than estimated.
　The NCCN guidelines recommend BRCA1 / 2 genetic testing for patients with TNBC ＜60 
years of age.  In the present study, most TNBC patients who underwent genetic testing were ＜
60 years of age （16 / 17 ; 94.1％）.  In this patient subgroup, BRCA1 / 2 mutations were detected 
in 18.6％ of patients （11 / 59）, whereas in those ＜ 50 years of age the rate of the mutation was 
23.3％（10 / 43）.  Thus, although the frequency of BRCA1 / 2 mutations in TNBC patients is high, 
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the rate tended to be higher in the lower age cut-off subgroup.
　Previous studies from Japan have reported similar frequencies of BRCA1 and BRCA2 muta-
tions 18–20）.  However, in the present study, the BRCA1 mutation was observed more frequently 
than the BRCA2 mutation.  The most likely explanation for this difference is the selection crite-
ria used for BRCA1 / 2 genetic testing.  In previous studies, the eligibility for testing was based 
primarily on FH, whereas in the present study TNBC was considered as an additional eligibility 
criterion for screening for BRCA1 / 2 mutations.
　In the present study, TNBC patients with an FH of breast or ovarian cancer frequently had 
BRCA1 / 2 mutations（9 / 13 ; 69.2％）.  These nine patients with mutations represented 31％ of 
TNBC patients with a positive FH.  Similar to the ndings of the present study, a previous 
study exploring the BRCA1 / 2 mutation frequency in the Greek population reported that, of 
a total of 403 patients with TNBC, 50 of 105 patients with an FH of cancer（48％） also had 
BRCA1 / 2 genetic mutations 21）.
　In the present study, two rearrangement mutations in BRCA1 were observed.  In patients 
from high-risk families, an intragenic rearrangement prevalence of 2％ and 12％ for each muta-
tion has been suggested 22-25）.  In 2011, Sluiter and van Rensburg reported that 81 rearrangements 
of BRCA1 had been found worldwide22）.  The frequency of these rearrangement mutations var-
ies in different races.  Notably, although rearrangement mutations in Asian and Hispanic popula-
tions have been reported, they are relatively more frequent in Caucasians 23–25）.  Although direct 
sequencing is the standard method used for BRCA1 / 2 genetic testing, this method cannot detect 
rearrangement mutations.  Thus, when no mutation is detected by the direct sequencing method, 
the MLPA test should be considered for the detection of BRCA1 / 2 genetic rearrangements 
in high-risk patients.  Indeed, the current procedures for BRCA1 / 2 genetic testing vary among 
countries, so there is some possibility that rearrangement mutations are missed, which would cre-
ate difculties when assessing differences in the frequency of these mutations in different popula-
tions 26，27）.
　Signicantly, determination of BRCA gene status is important not only in addressing the risk 
of breast and ovarian cancer, but also in selecting therapies.  DNA-damaging cytotoxic chemo-
therapies and poly（ADP-ribose） polymerase（PARP） inhibitors have recently been evaluated in 
germline BRCA mutation carriers 28, 29）.  PARP1 inhibitors have been demonstrated to elicit syn-
thetic lethality in combination with BRCA1 / 2 dysfunction in homologous recombination-decient 
breast cancers.  More recently, a Phase Ⅲ clinical trial of a PARP inhibiter in combination with 
standard chemotherapy for TN metastatic breast cancer showed no signicant difference in over-
all survival compared with standard chemotherapy alone 30）.  It is interesting to speculate whether 
the results may have been different if the participants had been preselected for BRCA1 / 2 muta-
tions.  Thus, further investigations are needed to determine whether BRCA1 / 2 mutations can 
predict therapeutic benet from PARP inhibitors in the treatment of TNBC.
　Together, the results of the present study suggest that the estimated prevalence of BRCA1 / 2 
mutations in the Japanese population is not less than that in Caucasian populations.  Thus, 
although breast cancer tends to occur at a younger age in Japanese than Caucasian popula-
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tions, guidelines like those of the NCCN appear to be suitable for predicting the occurrence of 
BRCA1 / 2 mutations in Japanese women.  In conclusion, although the number of patients in the 
present study was small, the data show a high BRCA1 / 2 mutagenesis rate in TNBC patients, 
especially in those ＜ 60 years of age or in combination with an FH of breast and/or ovarian 
cancer, as in Caucasian women.  We suggest these subsets of Japanese breast cancer patients 
meet the threshold for BRCA testing, as outlined in the NCCN guidelines.
　This study was approved by the Institutional Review Board of Showa University. 
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